Cantor Fitzgerald Weighs in on AbbVie FY2025 Earnings

AbbVie Inc. (NYSE:ABBV - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for AbbVie in a research report issued on Tuesday, April 22nd. Cantor Fitzgerald analyst C. Gould anticipates that the company will post earnings per share of $12.33 for the year. Cantor Fitzgerald has a "Overweight" rating and a $210.00 price target on the stock. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

Several other brokerages also recently commented on ABBV. Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Guggenheim reissued a "buy" rating and set a $214.00 price target on shares of AbbVie in a research note on Thursday, April 17th. StockNews.com cut AbbVie from a "strong-buy" rating to a "buy" rating in a report on Wednesday, April 9th. Truist Financial increased their target price on AbbVie from $211.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Finally, Raymond James reiterated an "outperform" rating and set a $220.00 target price (up from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $211.19.

AbbVie Trading Up 2.0 %

ABBV stock opened at $177.28 on Thursday. The firm's fifty day simple moving average is $197.30 and its two-hundred day simple moving average is $187.37. The stock has a market capitalization of $313.60 billion, a price-to-earnings ratio of 73.87, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. AbbVie has a twelve month low of $153.58 and a twelve month high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the previous year, the firm posted $2.79 earnings per share.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.70%. The ex-dividend date is Tuesday, April 15th. AbbVie's dividend payout ratio is presently 273.33%.

Insider Buying and Selling at AbbVie

In related news, EVP Timothy J. Richmond sold 29,917 shares of the firm's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the sale, the executive vice president now directly owns 44,284 shares of the company's stock, valued at $8,985,223.60. This trade represents a 40.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 5,778 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the transaction, the executive vice president now directly owns 22,381 shares of the company's stock, valued at $4,429,199.90. The trade was a 20.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,471 shares of company stock worth $23,426,451. Company insiders own 0.25% of the company's stock.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in ABBV. Fiduciary Advisors Inc. purchased a new stake in shares of AbbVie during the 4th quarter worth about $29,000. EnRich Financial Partners LLC boosted its position in AbbVie by 196.4% during the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after purchasing an additional 110 shares in the last quarter. Promus Capital LLC acquired a new stake in AbbVie in the fourth quarter valued at approximately $30,000. Bradley & Co. Private Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at approximately $31,000. Finally, Prudent Man Investment Management Inc. acquired a new position in shares of AbbVie during the 4th quarter worth approximately $32,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.